RFS analysis suggested that patients with breast cancer having low mRNA levels of FGFR2 had significantly worse RFS relative to the other groups (p = 0.04), whereas patients with high levels of ERBB4 had a better RFS than the opposite group (p = 9.5 × 10-5) (Figure 3D). Here, ERBB4 is linked to breast carcinoma.